5,6-二氢-2H-1,4-恶嗪-3-胺 | 747408-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪类
• 中文名称: 5,6-二氢-2H-1,4-恶嗪-3-胺
• 中文别名: 5-硝基-3-苯基-1H-吲唑
• 英文名称: morpholin-3-imine
• 英文别名: morpholin-3-ylideneamine；2H-1,4-Oxazin-3-amine, 5,6-dihydro-；3,6-dihydro-2H-1,4-oxazin-5-amine
• CAS: 747408-16-8
• 化学式: C₄H₈N₂O
• mdl: MFCD18814249
• 分子量: 100.12
• InChiKey: COPFSXJBOSOUGF-UHFFFAOYSA-N

物化性质

• 沸点：
  222.8±50.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6-二氢-2H-1,4-恶嗪-3-胺 、 2-bromo-3-isopropoxyacrolein 反应 1.5h， 生成 5,6-二氢-8H-咪唑并[2,1-c][1,4]恶嗪-2-甲醛
  参考文献：
  名称：

  Processes For Preparing Bicyclic Oxazine Carboxaldehyde and Beta-Lactamase Inhibitors

  摘要：

  本发明涉及制备双环氧噁啉羰基醛化合物1的工艺。本发明还涉及将化合物1用于制备□-内酰胺酶抑制剂的用途。

  公开号：

  US20090018332A1
• 作为产物：
  描述：

  morpholin-3-ylideneamine acetate 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 0.58h， 以91.6%的产率得到5,6-二氢-2H-1,4-恶嗪-3-胺
  参考文献：
  名称：

  Processes For Preparing Bicyclic Oxazine Carboxaldehyde and Beta-Lactamase Inhibitors

  摘要：

  本发明涉及制备双环氧噁啉羰基醛化合物1的工艺。本发明还涉及将化合物1用于制备□-内酰胺酶抑制剂的用途。

  公开号：

  US20090018332A1

文献信息

• Discovery and Characterization of (<i>R</i>)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-<i>c</i>][1,4]oxazin-4(9<i>H</i>)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
  作者：Antonia F. Stepan、Michelle M. Claffey、Matthew R. Reese、Gayatri Balan、Gabriela Barreiro、Jason Barricklow、Michael J. Bohanon、Brian P. Boscoe、Gregg D. Cappon、Lois K. Chenard、Julie Cianfrogna、Laigao Chen、Karen J. Coffman、Susan E. Drozda、Joshua R. Dunetz、Somraj Ghosh、Xinjun Hou、Christopher Houle、Kapil Karki、John T. Lazzaro、Jessica Y. Mancuso、John M. Marcek、Emily L. Miller、Mark A. Moen、Steven O’Neil、Isao Sakurada、Marc Skaddan、Vinod Parikh、Deborah L. Smith、Patrick Trapa、Jamison B. Tuttle、Patrick R. Verhoest、Daniel P. Walker、Annie Won、Ann S. Wright、Jessica Whritenour、Kenneth Zasadny、Margaret M. Zaleska、Lei Zhang、Christopher L. Shaffer

  DOI：10.1021/acs.jmedchem.7b00604

  日期：2017.9.28

  We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu(5) negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu(5) NAMs. Increasing the sp(3) character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu(5) NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c] [1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance.
• [EN] ANALOGS FOR THE TREATMENT OF DISEASE<br/>[FR] ANALOGUES POUR LE TRAITEMENT D'UNE MALADIE
  申请人：[en]INSILICO MEDICINE IP LIMITED

  公开号：WO2022179529A1

  公开（公告）日：2022-09-01

  Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.
• Processes For Preparing Bicyclic Oxazine Carboxaldehyde and Beta-Lactamase Inhibitors
  申请人：Kremer Kenneth Alfred Martin

  公开号：US20090018332A1

  公开（公告）日：2009-01-15

  The invention relates to processes for the preparation of the bicyclic oxazine carboxaldehyde Compound 1: The invention also relates to the use of Compound 1 in the preparation of □-lactamase inhibitors.

  本发明涉及制备双环氧噁啉羰基醛化合物1的工艺。本发明还涉及将化合物1用于制备□-内酰胺酶抑制剂的用途。